Sökning: WFRF:(Heyderman R) >
Population impact a...
Population impact and effectiveness of sequential 13-valent pneumococcal conjugate and monovalent rotavirus vaccine introduction on infant mortality: prospective birth cohort studies from Malawi
-
- King, C (författare)
- Karolinska Institutet
-
Bar-Zeev, N (författare)
-
Phiri, T (författare)
-
visa fler...
-
Beard, J (författare)
-
Mvula, H (författare)
-
Crampin, A (författare)
-
Heinsbroek, E (författare)
-
Hungerford, D (författare)
-
Lewckya, S (författare)
-
Verani, J (författare)
-
Whitney, C (författare)
-
Costello, A (författare)
-
Mwansambo, C (författare)
-
Cunliffe, N (författare)
-
Heyderman, R (författare)
-
French, N (författare)
-
Nakagomi, O (författare)
-
visa färre...
-
(creator_code:org_t)
- 2020-09-09
- 2020
- Engelska.
-
Ingår i: BMJ global health. - : BMJ. - 2059-7908. ; 5:9
- Relaterad länk:
-
https://gh.bmj.com/c...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RV) are key tools for reducing common causes of infant mortality. However, measurement of population-level mortality impact is lacking from sub-Saharan Africa. We evaluated mortality impact and vaccine effectiveness (VE) of PCV13 introduced in November 2011, with subsequent RV1 roll-out in October 2012, in Malawi.MethodsWe conducted two independent community-based birth cohort studies. Study 1, in northern Malawi (40000population), evaluated population impact using change-point analysis and negative-binomial regression of non-traumatic 14–51-week infant mortality preintroduction (1 January 2004 to 31 September 2011) and postintroduction (1 October 2011 to 1 July 2019), and against three-dose coverage. Study 2, in central Malawi (465 000 population), was recruited from 24 November 2011 to 1 June 2015. In the absence of preintroduction data, individual three-dose versus zero-dose VE was estimated using individual-level Cox survival models. In both cohorts, infants were followed with household visits to ascertain vaccination, socioeconomic and survival status. Verbal autopsies were conducted for deaths.ResultsStudy 1 included 20 291 live births and 216 infant deaths. Mortality decreased by 28.6% (95% CI: 15.3 to 39.8) post-PCV13 introduction. A change point was identified in November 2012. Study 2 registered 50 731 live births, with 454 deaths. Infant mortality decreased from 17 to 10/1000 live births during the study period. Adjusted VE was 44.6% overall (95% CI: 23.0 to 59.1) and 48.3% (95% CI: −5.9 to 74.1) against combined acute respiratory infection, meningitis and sepsis-associated mortality.ConclusionThese data provide population-level evidence of infant mortality reduction following sequential PCV13 and RV1 introduction into an established immunisation programme in Malawi. These data support increasing coverage of vaccine programmes in high-burden settings.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
King, C
-
Bar-Zeev, N
-
Phiri, T
-
Beard, J
-
Mvula, H
-
Crampin, A
-
visa fler...
-
Heinsbroek, E
-
Hungerford, D
-
Lewckya, S
-
Verani, J
-
Whitney, C
-
Costello, A
-
Mwansambo, C
-
Cunliffe, N
-
Heyderman, R
-
French, N
-
Nakagomi, O
-
visa färre...
- Artiklar i publikationen
-
BMJ global healt ...
- Av lärosätet
-
Karolinska Institutet